Werewolf Therapeutics (HOWL) Announces Mike Sherman to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Werewolf Therapeutics Appoints Mike Sherman to its Board of Directors
May 28, 2021 7:00 AM EDTCAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors.
The promise of immunotherapy has long been appreciated, but never fully realized. Werewolf has pioneered an elegant approach that may finally unleash that potential. This platform may translate to multiple drugs to address... More
